Ageing is a major risk factor for breast cancer (BC), with a peak incidence at around 75 years followed by a slight decline. The prevalence of HER2-overexpressing tumours in women aged 70 years and older ranges between 7% and 20%.
To date, the efficacy and safety data on trastuzumab in elderly patients are still limited, since lack of information on the elderly population is one of the main limits of oncological clinical trials in which enrolment is usually limited to women up to 65 years of age with good performance status.
Although retrospective series show that trastuzumab benefits and safety seem to be preserved in patients aged over 60 years [1] [2] [3] , cardiologic monitoring should be performed more carefully in these subjects, as in trastuzumab adjuvant trials the incidence of cardiac events increased with age.
A recent Spanish retrospective analysis of 45 early and advanced BC patients aged 70 years or over treated with trastuzumab showed that history of cardiac disease and/or diabetes was associated with increased incidence of cardiotoxicity [4] .
As in the aforementioned study, we retrospectively analysed the data of 22 HER2-overexpressing metastatic BC patients aged 65 years and older, treated with trastuzumab-based therapy.
Patients' characteristics are reported in Table 1 . In 15 patients (68%), trastuzumab was associated with chemotherapy (taxanes in 87% and vinorelbine in 13% of cases), while 7 patients (32%) received trastuzumab as single agent (weekly schedule in 72% of cases), which was later associated with chemotherapy in 5 patients. The median duration of trastuzumab-based treatment was 8 months (range 2.2-55).
With regard to cardiotoxicity, trastuzumab was discontinued for asymptomatic transient left ventricular ejection fraction (LVEF) decline <50% in two patients (9%) after 4.3 and 9.2 months, respectively. Three patients (14%) discontinued trastuzumab after a median time of 4.9 months for symptomatic cardiac disease (pulmonary hypertension with normal LVEF, myocardial infarction and congestive heart failure).
After discontinuation of trastuzumab, both the patients with asymptomatic LVEF decline recovered completely and in one case trastuzumab was reintroduced after 9 months. Two of three patients with symptomatic cardiotoxicity recovered completely and trastuzumab was restarted after 32 and 10 months, respectively.
Overall, 1 complete response (5%), 8 partial responses (36%), 11 (50%) stable diseases and 1 disease progression (5%) were documented. One patient was not assessable for objective response.
After a median follow-up of 72.3 months (range 10.2-83.2), the median time to progression was 7.8 months (range 2.5-87.9) and the median overall survival was 48.8 months (range 5.9-103.4): two patients have not experienced, yet, any disease progression after 48.8 and 87.9 months, respectively, and nine patients (41%) are still alive.
In conclusion, in spite of the limitations of a retrospective and small-sized analysis, our experience confirms the safety and the efficacy of trastuzumab in fit elderly BC patients, providing a careful monitoring of cardiac function, especially in the presence of cardiovascular risk factors (CRFs). [3, 4] . Its mechanism of action, along with the available in vitro data [5] , indicates that this agent may represent a useful treatment option for male breast cancer patients.
In this retrospective chart review, cases with male breast cancer treated with fulvestrant were evaluated. Eligible patients derived from the Department of Medicine I/ Division of Oncology, Vienna, Austria and from the 1st Propaedeutic Surgical Department of Hippocrateio Hospital, University of Athens, Athens, Greece. In all cases, fulvestrant was administered at a loading dose of 500 mg on day 1 followed by 250 mg on day 14 and monthly thereafter, until disease progression. The response was assessed according to the RECIST criteria. Overall survival (OS) was defined as the interval between initial diagnosis and time of death, whereas time to treatment progression (TTP) was defined as the interval between initiation of fulvestrant and time of progression.
Fourteen men aged 53-76 years (63.5 ± 6.8, mean ± SD) were included in this case series. Patients' characteristics are depicted in Table 1 . None of the patients had received chemotherapy treatment for metastatic disease. In the majority of cases, fulvestrant was given as a second-line hormonal treatment in six (42.9%) patients, as a third-line agent in seven (50%) patients and as fourth line in one (7.1%) patient. In all cases, fulvestrant was tolerated well, without grade 3 and 4 adverse events being reported. Regarding the best response, partial response (PR) was noted in three (21.4%) patients, stable disease (SD) in seven (50%) patients, whereas progressive disease (PD) was observed in four (28.6%) patients. The median time to treatment progression (TTP) was equal to 5 months, ranging between 2 and 7 months. The median overall survival (OS) was 61.5 months. The study was approved by local ethics committees. According to our knowledge, this is the largest case series reported in the literature with fulvestrant administration in male breast cancer. 
